BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 9364543)

  • 1. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
    Aapro MS
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
    Mattson K; Saarinen A; Jekunen A
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in the management of advanced non-small cell lung cancer.
    Miller VA
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; DeschĂȘnes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer.
    Chang AY; DeVore R; Johnson D
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):19-21. PubMed ID: 8610231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
    Belani CP;
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
    Krug LM; Miller VA
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):24-6; discussion 41-2. PubMed ID: 10585005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
    Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
    [No Abstract]   [Full Text] [Related]  

  • 16. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
    Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
    Miller VA; Kris MG
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer.
    Miller V
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):12-4. PubMed ID: 10437745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.